TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02269605
Drug: Bryostatin 1 (20ug/m2)
Normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: Bryostatin 1 (20ug/m2) at single dose
Study: NCT03492112
Drug: Sofosbuvir/velpatasvir
Normalized name: SOFOSBUVIR/VELPATASVIR
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
Study: NCT03492112
Drug: Glecaprevir/pibrentasvir
Normalized name: GLECAPREVIR/PIBRENTASVIR
DrugBank: Pibrentasvir (DB13878)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
Study: NCT01559285
Drug: 0.75% ropivacaine concentration
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.75% ropivacaine 8ml was injected epidurally after induction of general anesthesia
Study: NCT01559285
Drug: 0.375% ropivacaine concentration
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.375% ropivacaine 8ml was injected epidurally after induction of general anesthesia
Study: NCT01559285
Drug: 0.2% ropivacaine concentration
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2% ropivacaine 8ml was injected epidurally after induction of general anesthesia
Study: NCT03808454
Drug: PRP
Normalized name: PRP
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigators draw 10cc of blood and concentrate the blood to get the platelet rich plasma
Study: NCT00114478
Drug: albuterol (salbutamol)
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01972984
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be instructed to take one tablet of anastrozole orally per day with fluids. This tablet will be taken at the same time every day. Participants will be given a drug diary to record drug administration and aid in drug compliance. Should the participant miss a dose they will be asked to record it in their diary and resume the normal dose schedule the next day.
Study: NCT03116269
Drug: Cilostazol 100mg
Normalized name: CILOSTAZOL 100MG TAB
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03116269
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00313898
Drug: sildenafil (viagra)
Normalized name: sildenafil Oral Tablet [Viagra]
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03274661
Drug: Pembrolizumab 200 mg Q3W
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg Intravenous Infusion every 3 weeks administered on Day 1 of each 3 week cycle
Study: NCT03921541
Drug: Pegzilarginase
Normalized name: Pegzilarginase
DrugBank: Pegzilarginase (DB14780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
Study: NCT04618965
Drug: Intrathecal dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Each patient will receive dexmedetomidine 5 μg diluted in 0.5ml saline and hyperbaric Bupivacaine 10 mg in 2.5 ml with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
Study: NCT04618965
Drug: Intravenous dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Each patient will receive intravenous dexmedetomidine started at a loading dose of 1 μg/kg diluted in 50 ml saline and administered within 10 min as a loading dose, followed by maintenance at a dose of 0.4 μg/kg/h diluted in 200 ml saline till the end of surgery and hyperbaric Bupivacaine 10 mg in 2.5 ml total volume.
Study: NCT04212065
Drug: buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: To improve compliance with medication assisted therapy, decrease relapse and neonatal abstinence syndrome, we propose a randomized control trial of long acting subcutaneous buprenorphine compared to short acting sublingual buprenorphine/naloxone administration in pregnant and lactating women.
Study: NCT02046187
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients receive standard dose (75 mg/kg/day) temozolomide by mouth daily with radiation for 6 weeks. patients will also have standard maintenance dose (150-200 mg/kg/day) for five days each month for 12 cycles following radiation course.
Study: NCT01232907
Drug: L-Carnitine
Normalized name: L-Carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-Carnitine, a pharmaceutical product, for the treatment of fatigue in persons with spinal cord injury will be used for this study. L-Carnitine is a nutrient normally obtained in the fat from meat. It promotes fatty acid oxidation of muscle, thereby promoting efficient energy production. Treatment with L-Carnitine has been shown to produce clinically significant improvement in fatigue in persons with multiple sclerosis (MS), cancer, and in aging populations. While the causes of fatigue in persons with SCI may be multifactorial, successful use of L-Carnitine in MS-related fatigue suggests it may have a role in SCI. Standard treatment will entail daily dosages of 1980 milligrams of L-Carnitine (three 330 mg tablets in the morning and three 330 mg tablets in the evening) for 4 weeks.
Study: NCT03526432
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered by IV infusion at 15mg/kg on Day 1 of every 21-days cycle.
Study: NCT03526432
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, loss of clinical benefit as determined by the investigator.
Study: NCT02264041
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05862441
Drug: SA
Normalized name: SA
DrugBank: Sulfanilamide (DB00259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis.
Study: NCT04834115
Drug: Ivermectin Tablets
Normalized name: Ivermectin Tablets
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ivermectin at a one time dose
Study: NCT01805570
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Prasugrel before PPCI. The loading dose of Prasugrel will be 60 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
Study: NCT01805570
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Ticagrelor before PPCI. The loading dose of Ticagrelor will be 360 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
Study: NCT00132912
Drug: SCH 530348
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03868566
Drug: SNP-612 dose1
Normalized name: SNP-ACTH (1-39)
DrugBank: SNP-ACTH (1-39) (DB18544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take dose1 once a day orally for 12 weeks
Study: NCT03868566
Drug: SNP-612 dose2
Normalized name: SNP-ACTH (1-39)
DrugBank: SNP-ACTH (1-39) (DB18544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take dose2 once a day orally for 12 weeks
Study: NCT01371565
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mifepristone at doses from 300mg/day up to 1200mg/day
Study: NCT02170012
Drug: PF-06743649
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tablet once daily dosing for 14 days
Study: NCT02170012
Drug: PF-06743649
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To be decided dose, tablet once daily dosing for 14 days
Study: NCT02852434
Drug: Lidocaine Gel (2%)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02852434
Drug: Lidocaine Paracervical Block (1%)
Normalized name: Ivy Block
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04116047
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04116047
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT05406999
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000 mg (250 mg×4 tablets) once daily, orally
Study: NCT05406999
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 160 mg (40 mg× 4 tablets) once daily, orally.
Study: NCT05406999
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 240 mg (60 mg×4 tablets) once daily, orally.
Study: NCT05406999
Drug: Darotamide
Normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 600 mg (300 mg × 2 tablets) twice daily, orally.
Study: NCT05406999
Drug: Rezvilutamide
Normalized name: Rezvilutamide
DrugBank: Rezvilutamide (DB19133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg (80 mg × 3 tablets) once daily orally
Study: NCT05406999
Drug: PARP inhibitor
Normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PARP inhibitors will be determined by the investigators at separate centers. The dosage and frequency of administration will be consistent with the prescribing information. Available drugs include olaparib, fluzoparib, pamiparib, talazoparib ect.
Study: NCT00884000
Drug: Genotropin
Normalized name: Genotropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00884000
Drug: Zomacton
Normalized name: Zomacton
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01166763
Drug: vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsules, 10,000 IU per week for 6 months
Study: NCT01528254
Drug: Placebo of vildagliptin
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT01528254
Drug: vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: One tablet (50 mg oral) of vildagliptin in the morning and one tablet in the evening with or without food.
Study: NCT01528254
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Twice daily (bid) regimen during or after meals at the same time as vildagliptin.
Study: NCT01822405
Drug: pentoxifylline with tocopherol
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day,oral during 6 months
Study: NCT03569007
Drug: Larazotide
Normalized name: Larazotide
DrugBank: Larazotide (DB05645)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic 8-amino acid peptide formulated as enteric-coated beads in gelatin capsules
Study: NCT00271570
Drug: Infliximab (Remicade)
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remicade was 5 mg/kg IV (single dose)
Study: NCT04034173
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab 6 mg/kg BW as 60-min i.v. infusion\* D1~\*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.
Study: NCT04034173
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1
Study: NCT04034173
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1
Study: NCT01081938
Drug: INSULIN GLARGINE
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: Lantus® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device.~Dose regimen: Single daily dose of Insulin Glargine
Study: NCT01081938
Drug: INSULIN GLULISINE
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form: Apidra® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device~Dose regimen:~Arm1: Every 6 hours Arm2: several daily dose according to sliding scale of Insulin Glargine
Study: NCT00482456
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04034173
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 400 mg/m² BSA, bolus, D1 5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2
Study: NCT00438087
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: methylprednisolone administrated intra and post operatively
Study: NCT04385836
Drug: alpha one antitrypsin inhalation
Normalized name: alpha 1-antitrypsin
DrugBank: Trypsin (DB11237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: - we will give 8 ml of intravenous alpha one antitrypsin (alpha1-proteinase inhibitor (AATD)Glassia 50 ml) as nebulizer every 12 hours for 5 days
Study: NCT02786511
Drug: Safety and efficacy assessments
Normalized name: cytarabine and daunorubicin
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term implications of autologous transplant
Study: NCT02172742
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day).
Study: NCT04455802
Drug: Buprenorphine or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The double blind, double dummy design necessitates that both drugs be on an identical schedule. The 4-hour dosing allows for this pairing. If a patient is randomized to the buprenorphine arm, medication administration will follow an every 8-hour dosing but medication will be substituted with placebo during the intermediary time point.
Study: NCT04455802
Drug: Morphine or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If a patient is randomized to the morphine arm, morphine will be given every 4 hours. Placebo will also be given at the same frequency as a faux drug.
Study: NCT04918264
Drug: Fluoropyrimidine treatment (5-FU or capecitabine) and dosage
Normalized name: Hongo Killer Treatment
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In each group with an uracil dosage; at cycle 1; capecitabine or continuous 5-FU dose percentage will be evaluate retrospectively in our database
Study: NCT00005898
Drug: anti-thymocyte globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005898
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005898
Drug: filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00005898
Drug: fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005898
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03622931
Drug: Romiplostim
Normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02563353
Drug: teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide, 20 microgram/day. 24 months of treatment.
Study: NCT00225758
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1500 mg po daily for 26 weeks or longer
Study: NCT01524692
Drug: Dovitinib (TKI258)
Normalized name: Dovitinib
DrugBank: Dovitinib (DB05928)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg orally on a 5-days on/2-days off schedule each week of a 4-week (28-day) cycle. Treatment will continue until progression as defined by RECIST, unacceptable adverse events, patient refusal to continue on study, or physician's decision to withdraw the patient.
Study: NCT03403595
Drug: 177Lu-EB-PSMA-617
Normalized name: 177Lu-PSMA-617
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: accepted intravenous injection of 177Lu-EB-PSMA-617 and monitored at 2, 24, 72, 120 and 168 hours post-injection.
Study: NCT01721330
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Up to 100mg of Naltrexone once a day for 6 weeks
Study: NCT00326456
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5 intravenously on day 1 every 3 weeks
Study: NCT00326456
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175 mg/m2 intravenously on day 1 every 3 weeks
Study: NCT02883153
Drug: Zirconium-89 girentuximab PET/CT
DrugBank: Girentuximab (DB05304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thirty patients (suspected of ccRCC) will be included in whom conventional diagnostics are inconclusive. During a multidisciplinary team (MDT) the hypothetical next step in the clinical process will be noted. Subsequently, in these patients a Zirconium-89-girentuximab PET/CT will be performed 4-5 days after single intravenous injection of 5 mg Zirconium-89-girentuximab (37 MBq). The results of the PET/CT will be discussed during the MDT and will be used to decide what the next step in the clinical process will be. This step will be compared with the hypothetical next step from the MDT before the scan. Whether or not the PET/CT scan had impact on clinical decision making will be assessed for each individual patient.
Study: NCT02235012
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KETAMINE PANPHARMA 250 mg/5mL, solution for infusion :~* Initial rapid infusion of 0,23 mg/kg~* Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~* Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min
Study: NCT02049944
Drug: Cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who are undergoing an elective cesarean section at term will receive 3 grams of Cefazolin at least 30, but no more than 60 minutes prior to skin incision administered through an intravenous line.
Study: NCT02106559
Drug: porfimer sodium
Normalized name: Porfimer Sodium
DrugBank: Porfimer sodium (DB00707)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00004941
Drug: monoclonal antibody cA2
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02453191
Drug: Talimogene Laherparepvec
Normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Talimogene Laherparepvec
Study: NCT02636322
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02636322
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02636322
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02636322
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02636322
Drug: Vincristine Sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00513864
Drug: Dextromethorphan
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one time dose - 0.3mg/kg PO
Study: NCT00513864
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one time dose - 0.15mg/kg IV
Study: NCT02502071
Drug: sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will receive 2 doses of 1950mg sodium bicarbonate
Study: NCT02696577
Drug: Low dose aspirin
Normalized name: Adult Low Dose Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02696577
Drug: Omega 3
Normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00158470
Drug: efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00158470
Drug: didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00158470
Drug: lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes